The current financial score of Bio-Techne Corp is 9.53. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 321.19M, representing a year-over-year increase of 1.33%, while its net profit experienced a year-over-year increase of 408.68%.
The current valuation score of Bio-Techne Corp is 7.30. Its current P/E ratio is 102.19, which is 39.86% below the recent high of 142.92 and 67.00% above the recent low of 33.73.
The current earnings forecast score of Bio-Techne Corp is 6.38. The average price target is 70.94, with a high of 79.00 and a low of 50.00.
The current price momentum score of Bio-Techne Corp is 1.08. Currently, the stock price is trading between the resistance level at 72.47 and the support level at 71.88, making it suitable for range-bound swing trading.
The current institutional shareholding score of Bio-Techne Corp is 10.00. The latest institutional shareholding proportion is 113.81%, representing a quarter-over-quarter increase of 3.16%. The largest institutional shareholder is Ruane Cunniff, holding a total of 3.35M shares, representing 3.68% of shares outstanding, with 173.37% increase in holdings.
The current risk assessment score of Bio-Techne Corp is 6.68. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.